These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 9689574

  • 1. Resistance of HIV to antiretroviral agents. Basic concepts.
    Dianzani F, Antonelli G, Turriziani O.
    J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):19-22. PubMed ID: 9689574
    [No Abstract] [Full Text] [Related]

  • 2. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA, Reedijk M.
    J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
    [No Abstract] [Full Text] [Related]

  • 3. [New trends in HIV].
    Volkert R.
    Dtsch Med Wochenschr; 1998 Sep 18; 123(38):A7. PubMed ID: 9787287
    [No Abstract] [Full Text] [Related]

  • 4. [Human immunodeficiency virus and antiretroviral therapy resistance].
    Quirós E, Torti C, Carosi G.
    Enferm Infecc Microbiol Clin; 2000 May 18; 18(5):234-7. PubMed ID: 10974768
    [No Abstract] [Full Text] [Related]

  • 5. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA.
    AIDS Clin Rev; 2000 May 18; ():139-91. PubMed ID: 10999220
    [No Abstract] [Full Text] [Related]

  • 6. Zidovudine (Retrovir).
    Res Initiat Treat Action; 2000 Mar 18; 6(1):6-7. PubMed ID: 11708188
    [No Abstract] [Full Text] [Related]

  • 7. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L, Johnson M, Graham N, Shaefer M, St Clair M.
    J Hum Virol; 1999 Mar 18; 2(5):290-5. PubMed ID: 10551735
    [Abstract] [Full Text] [Related]

  • 8. [Resistance to nucleoside reverse transcriptase inhibitors].
    Leal M, Santamaría JM.
    Enferm Infecc Microbiol Clin; 2001 Feb 18; 19(Monografico):26-9. PubMed ID: 11428055
    [No Abstract] [Full Text] [Related]

  • 9. [Resistance to non-nucleoside reverse transcriptase inhibitors].
    Casado JL, López JC, Viciana P.
    Enferm Infecc Microbiol Clin; 2001 Feb 18; 19(Monografico):30-3. PubMed ID: 11428057
    [No Abstract] [Full Text] [Related]

  • 10. [AIDS drug in the correct form].
    Schenk M.
    Dtsch Med Wochenschr; 1998 Sep 04; 123(36):A9. PubMed ID: 9765604
    [No Abstract] [Full Text] [Related]

  • 11. HIV pathogenesis and activation of CD4 cells.
    Albrecht H.
    AIDS Clin Care; 2001 Oct 04; 13(10):99. PubMed ID: 11590927
    [Abstract] [Full Text] [Related]

  • 12. [Resistance to antiretroviral drugs: a clinical, public health and health policy debate].
    Guerra Romero L, Parras Vázquez F.
    Med Clin (Barc); 2000 Oct 07; 115(11):428-30. PubMed ID: 11093847
    [No Abstract] [Full Text] [Related]

  • 13. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.
    Antivir Ther; 2000 Mar 07; 5(1):7-14. PubMed ID: 10846586
    [Abstract] [Full Text] [Related]

  • 14. Selective expansion of a minor proportion of drug-resistant HIV-1 by antiretroviral pressure in vitro.
    Roberts BD, Pau CP, Weinstock H, Heneine W, Butera ST.
    AIDS; 2000 Dec 01; 14(17):2797-8. PubMed ID: 11125904
    [No Abstract] [Full Text] [Related]

  • 15. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J, Brooks JT, Baker R, Hoffman M, Moorman A, Novak R, HOPS Investigators.
    Antivir Ther; 2007 Dec 01; 12(6):957-62. PubMed ID: 17926650
    [Abstract] [Full Text] [Related]

  • 16. HIV resistance testing proves its value.
    Proj Inf Perspect; 1999 Sep 01; (28):14. PubMed ID: 11367356
    [Abstract] [Full Text] [Related]

  • 17. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
    Ross L, Henry K, Paar D, Salvato P, Shaefer M, Fisher R, Liao Q, St Clair M.
    J Hum Virol; 2001 Sep 01; 4(4):217-22. PubMed ID: 11694850
    [Abstract] [Full Text] [Related]

  • 18. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM.
    J Infect Dis; 2000 Feb 01; 181(2):491-7. PubMed ID: 10669331
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA, Leriche-Guerin K, Regis C, Bordes I, Cotte L, Detmer J, Kolberg J, Ritter J, Trépo C.
    J Med Virol; 2000 Jul 01; 61(3):352-9. PubMed ID: 10861645
    [Abstract] [Full Text] [Related]

  • 20. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, Calvez V.
    J Med Virol; 2004 Jan 01; 72(1):162-5. PubMed ID: 14635026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.